LONDON and MADRID, Oct. 16, 2025 (GLOBE NEWSWIRE) — StepStone Real Estate (SRE), the real estate arm of StepStone Group (Nasdaq: STEP) and GREYKITE (GK), the independent European real estate investment firm, announce the planned recapitalization of Vitalia, Spain’s second largest care home owner-operator, through the agreement to acquire a majority interest in Vitalia from Vivaly Investments BV, a portfolio investment of CVC Fund VI and Portobello Capital Fund III, and the commitment of over €500 million in growth capital. Both Vivaly Investments BV and Vitalia’s founder and senior management team will be retaining minority stakes. GREYKITE will be acting as the general partner on behalf of the shareholders, leading day to day management of the investment. The transaction remains subject to customary regulatory approvals. Vitalia...

First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced that the first patient in the U.S. has been dosed with SIM0505 in the ongoing Phase 1 trial (NCT06792552), which is evaluating safety, tolerability, pharmacokinetics and efficacy in patients with advanced solid tumors. SIM0505 is a novel antibody drug conjugate directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase...

NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel’s Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 for recurrent high-grade glioma. “I’m honored to join Candel’s Research Advisory Board during this pivotal stage for the Company,” said...

Strengthens balance sheet to support continued development of its flagship Tanbreez rare earth project in Greenland NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that it has entered into a securities purchase agreement with a fundamental institutional investor to raise $50,000,000 of gross proceeds via a private investment in public equity (“PIPE”) transaction. The Company intends to use the net proceeds from the offering to help fund the development of its 4.7 billion metric ton rare earth deposit, Tanbreez, in Greenland. “This financing further strengthens our balance sheet and demonstrates continued investor confidence in Critical Metals Corp as we advance our strategic portfolio of critical...

Collaboration aims to accelerate the adoption of advanced gene editing technologies in and deliver high-performance traits that support more sustainable and productive rice production in India SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced its agreement with AgVayā, a strategic growth advisory firm that partners with leading innovators, to develop strategies and solutions for the Indian agriculture market. Together, the companies will define market strategies, build partnerships, and accelerate the introduction of Cibus’ gene editing technologies into India’s rice seed industry, supporting the development of more resilient and productive rice varieties that are critical to...

DUBLIN, Ireland, Oct. 16, 2025 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of full-service energy engineering, advisory, and utility solutions, today announced that it has signed a Subscription and Shareholders Agreement (the “Joint Venture Agreement”) with Alien Fuel (Proprietary) Limited (“Alien Fuel”) to formally establish their joint venture vehicle, Biosteam Energy Proprietary Ltd (“Biosteam Energy”), for the Fairfield Industrial Decarbonization Project (the “Fairfield Project”) in Howick, KwaZulu-Natal, South Africa. Under the joint venture structure, Fusion Fuel will hold a 51% ownership stake in Biosteam Energy, with Alien Fuel retaining 49%. Under the terms of the Fairfield Project and the Joint Venture Agreement, Biosteam Energy will manage the financing,...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function  Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing IND cleared by FDA in September 2025 and expected to clear in China in Q4’25. Phase 1 study of DNTH212 expected to initiate in Q4’25 with top-line results in healthy volunteers in 2H’26 Pro forma estimated cash of ~$525 million; reaffirms runway into 2028 Investor conference...

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

Now through Dec. 31, donations to Beelieve will be matched to fund Bee participation for schools in under-resourced communitiesBeelieveScripps National Spelling Bee, Scripps Howard Fund launch campaign to empower next generation of spellersCINCINNATI, Oct. 16, 2025 (GLOBE NEWSWIRE) — The Scripps Howard Fund and the Scripps National Spelling Bee have launched “Beelieve,” a new campaign to expand access to the Bee for students from schools in under‑resourced communities. In celebration of the Bee’s 100th anniversary this year, the first $100,000 in donations will be matched by the Adam R. Scripps Foundation. Beelieve will provide free enrollment and program resources to partner Title 1 schools during the 2025-26 school year so even more students can benefit from the Bee’s yearlong program. “Every student deserves the chance...